University Hospitals Coventry and Warwickshire NHS Trust (UHCW) has become the first healthcare organisation in the world to recruit a patient into a major new international cancer trial.
The Add-Aspirin Trial, funded by Cancer Research UK and the National Institute for Health Research, is studying the effects of taking aspirin daily for five years after treatment for an early stage cancer of the breast, stomach, oesophagus, prostate or bowel. The study hopes to recruit 11,000 patients in the UK and in India.
Consultant clinical oncologist, Dr Martin Scott-Brown, who is leading the study at UHCW, said: “This is a very exciting trial that we hope will have a major impact on reducing the risk of cancer recurrence.
“Our team has worked very hard to be absolutely ready to offer this trial to patients as soon as it opened as we believe that through trials we will improve our treatments for all our patients with cancer.”
The study, sponsored by University College London (UCL) and co-ordinated by the Medical Research Council Clinical Trials Unit at UCL, opened on Tuesday October 6 and it took just two days for UHCW to get the first patient recruited to the trial.
The trial team have advised that aspirin is not suitable for everyone and can have serious side effects.